...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Ultrasound: JCU >Y In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy: A report of three cases and a literature review
【24h】

Y In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy: A report of three cases and a literature review

机译：Y在产前倍他米松治疗后微囊性先天性囊性腺瘤样畸形的子宫内消融：三例报告并文献复习

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Fetal congenital cystic adenomatoid malformation (CCAM) can progress to nonimmune hydrops, and the mortality rate of CCAM with hydrops is reported to be nearly 100%. We describe three microcystic CCAM cases in which the fetal condition improved after maternal betamethasone therapy. The median gestational age at steroid administration was 23 5/7 weeks' gestation. The CCAM decreased in size in all cases. Our series showed a 100% hydrops resolution rate (2/2) and a 100% survival rate (3/3). Our experience suggests the efficacy of betamethasone treatment on fetuses with microcystic CCAM who have fluid collection or are at risk of developing hydrops. (c) 2014 Wiley Periodicals, Inc. J Clin Ultrasound43:451-457, 2015
机译：胎儿先天性囊性腺瘤样畸形（CCAM）可以发展为非免疫性积液，据报道，合并积液的CCAM的死亡率接近100％。我们描述了三例微囊性CCAM病例，其中母体倍他米松治疗后胎儿病情改善。给予类固醇激素的平均胎龄为23 5/7周。在所有情况下，CCAM的大小均减小。我们的系列显示了100％的积水分辨率（2/2）和100％的存活率（3/3）。我们的经验表明，倍他米松治疗具有微囊性CCAM的胎儿的功效，这些胎儿有积液或有发生积液的危险。 （c）2014 Wiley Periodicals，Inc.《临床超声杂志》 43：451-457，2015

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号